EBCC 2024 | Immune-related adverse events in breast cancer patients taking ICIs

Michail Ignatiadis, MD, PhD, Jules Bordet Institute, Brussels, Belgium, highlights adverse events from immune checkpoint inhibitor (ICI) treatment. Patients receiving checkpoint inhibitor treatment may experience short term issues such as hepatitis, fatigue, and hematological toxicity. Less common long term complications include autoimmune disorders, diabetes, and endocrinopathy, and in extreme cases include fatal cardiopulmonary toxicity. To minimize the burden of treatment adverse effects, more research is needed about which patients do not benefit from checkpoint inhibitor. This interview took place at the 14th European Breast Cancer Conference (EBCC) in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.